港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

邁威生物-B

21.700

-0.320-1.45%

成交量：9.86萬

成交額：214.97萬

市值：97.00億

市盈率：-7.65

高：22.400

開：22.400

低：21.480

收：22.020

52周最高：31.460

52周最低：20.160

股本：4.47億

香港流通股本：4,713.02萬

量比：0.33

換手率：0.21%

股息：- -

股息率：- -

每股收益(LYR):-2.835

淨資產收益率：-118.88%

總資產收益率：-11.80%

市淨率：77.84

市盈率(LYR):-7.65

市銷率: 11.16

資料載入中...

總覽公司新聞資訊公告

邁威生物－Ｂ(02493)股價下跌5.063%，現價港幣$24.0

阿斯达克财经

邁威生物：截至2026年一季度末，公司在手現金及現金等價物餘額為14.83億元

邁威生物跌6.85% 2022年上市募34.77億國泰海通保薦

邁威生物－Ｂ(02493)股價顯著下跌11.253%，現價港幣$22.24

阿斯达克财经

邁威生物-B(02493.HK)：9MW5211注射液臨床試驗申請獲得國家藥品監督管理局批准

邁威生物：9MW5211注射液兩項適應症臨床試驗獲批覆蓋多發性硬化、炎症性腸病

《股市簡訊》中國邁威生物A/H股齊漲，血液瘤藥物臨床試驗獲批

邁威生物(688062.SH)：注射用6MW5311臨床試驗申請獲國家藥監局批准

智通港股早知道 | 八部門發布《關於加快「人工智能+消費」發展的實施意見》伊朗軍方宣佈關閉霍爾木茲海峽

邁威生物-B(02493)：9MW2821在2026年歐洲腫瘤內科學會婦科腫瘤年會 (ESMO Gynae)以口頭報告和壁報形式報告最新臨床數據

邁威生物-B(02493)：華俊獲委任為授權代表

邁威生物-B(02493)：桂勳獲選舉為職工代表董事

邁威生物完成董事會換屆：劉大濤當選董事長並任總經理

邁威生物－Ｂ(02493)股價上升5.098%，現價港幣$26.8

阿斯达克财经

港股異動 | 邁威生物-B(02493)升逾3% 旗下邁威視與維眸生物達成戰略合作聚焦眼科炎症及眼免疫領域

《股市簡訊》中國邁威生物勁揚6.4%，美國FDA批准其血液瘤藥物臨床試驗

港股異動 | 邁威生物-B(02493)午前升逾6% 注射用6MW5311臨床試驗申請獲得FDA許可

邁威生物(02493.HK)注射用6MW5311臨床試驗申請獲FDA許可

阿斯达克财经

邁威生物(688062.SH)：注射用6MW5311臨床試驗申請獲得FDA許可

重磅單品凸顯聯用潛力，邁威生物-B(02493)商業化確定性逐步兑現

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/02493/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02493","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02493\",,,,,undefined,":{"symbol":"02493","market":"HK","secType":"STK","nameCN":"邁威生物-B","latestPrice":21.7,"timestamp":1787815982418,"preClose":22.02,"halted":0,"volume":98600,"delay":0,"changeRate":-0.014532243415077216,"floatShares":47130200,"shares":447000000,"eps":-2.834803173060342,"marketStatus":"交易中","change":-0.32,"latestTime":"08-27 15:33:07","open":22.4,"high":22.4,"low":21.48,"amount":2149664,"amplitude":0.04178,"askPrice":21.82,"askSize":1200,"bidPrice":21.68,"bidSize":400,"shortable":0,"etf":0,"ttmEps":-2.7193111919356614,"tradingStatus":2,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1787818200000},"marketStatusCode":2,"adr":0,"listingDate":1777305600000,"exchange":"SEHK","adjPreClose":22.02,"openAndCloseTimeList":[[1787794200000,1787803200000],[1787806800000,1787817600000]],"volumeRatio":0.330226,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"邁威生物-U","latestPrice":29.73,"timestamp":1787814000000,"preClose":29.75,"halted":0,"volume":6953200,"delay":0,"premium":"-37.43"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02493\",,,,,undefined,":{"symbol":"02493","floatShares":47130200,"roa":"-11.80%","roe":"-118.88%","lyrEps":-2.834803,"volumeRatio":0.330226,"shares":447000000,"dividePrice":0,"high":22.4,"amplitude":0.04178,"preClose":22.02,"low":21.48,"week52Low":20.16,"pbRate":"77.84","psRate":"11.16","week52High":31.46,"institutionHeld":0,"latestPrice":21.7,"committee":-0.5,"eps":-2.834803173060342,"divideRate":0,"volume":98600,"delay":0,"ttmEps":-2.7193111919356614,"open":22.4,"prevYearClose":27.64,"prevWeekClose":21.94,"prevMonthClose":21.02,"prevQuarterClose":23.32,"fiveDayClose":22.08,"twentyDayClose":20.96,"sixtyDayClose":22.7,"earningDate":1788019200000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02493\",params:#limit:5,,,undefined,":[{"date":"2026-08-30","symbol":"02493","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788053400000,"name":null,"time":"","dateTimestamp":1788019200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02493\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02493\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1783699200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02493\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02493","date":"2026-08-26","current":-7.979962,"percent":0.658824,"low":-17.302507,"twenty":-15.744841,"median":-14.662586,"eighty":-13.168057,"high":-12.171256,"avg":-14.58866,"sd":1.330114,"marketCap":14856734792.95},"quantilePoints":[{"date":"2026-04-24","current":-15.289641,"twenty":-16.199622,"median":-15.659552,"eighty":-15.437605,"marketCap":17000217748.15},{"date":"2026-04-30","current":-16.640195,"twenty":-16.379645,"median":-15.593679,"eighty":-15.250239,"marketCap":17562577595.07},{"date":"2026-05-08","current":-16.416983,"twenty":-16.631559,"median":-16.471868,"eighty":-15.350449,"marketCap":17380742435.69},{"date":"2026-05-15","current":-16.009725,"twenty":-16.685787,"median":-16.416983,"eighty":-15.606854,"marketCap":16994157190.87},{"date":"2026-05-22","current":-15.517615,"twenty":-16.631559,"median":-16.0746,"eighty":-15.529829,"marketCap":16434142933.1},{"date":"2026-05-29","current":-14.179755,"twenty":-16.597014,"median":-15.628209,"eighty":-15.240388,"marketCap":15069483633.31},{"date":"2026-06-05","current":-12.517432,"twenty":-16.559668,"median":-15.581594,"eighty":-14.26556,"marketCap":13322161865.15},{"date":"2026-06-12","current":-13.472006,"twenty":-16.526753,"median":-15.469041,"eighty":-13.356302,"marketCap":14328406594.37},{"date":"2026-06-18","current":-12.99766,"twenty":-16.438937,"median":-15.265014,"eighty":-12.92448,"marketCap":13857073336},{"date":"2026-06-26","current":-12.199681,"twenty":-16.378066,"median":-14.95714,"eighty":-12.901569,"marketCap":12942815528.08},{"date":"2026-07-03","current":-14.979824,"twenty":-16.23102,"median":-14.955208,"eighty":-12.918972,"marketCap":15904197681.19},{"date":"2026-07-10","current":-14.849801,"twenty":-16.061625,"median":-14.902504,"eighty":-12.970767,"marketCap":15746801597.92},{"date":"2026-07-17","current":-14.420221,"twenty":-16.08484,"median":-14.955208,"eighty":-13.013901,"marketCap":15345691723.29},{"date":"2026-07-24","current":-14.443737,"twenty":-16.025201,"median":-14.968482,"eighty":-13.071825,"marketCap":15374169818.76},{"date":"2026-07-31","current":-13.354051,"twenty":-15.926439,"median":-14.902504,"eighty":-13.105062,"marketCap":14241292067.7},{"date":"2026-08-07","current":-14.221458,"twenty":-15.744727,"median":-14.562278,"eighty":-13.056126,"marketCap":15195777985.44},{"date":"2026-08-14","current":-15.770582,"twenty":-15.789139,"median":-14.806347,"eighty":-13.105062,"marketCap":16872365889.11},{"date":"2026-08-21","current":-14.469039,"twenty":-15.760286,"median":-14.849801,"eighty":-13.131915,"marketCap":15514103639.81},{"date":"2026-08-26","current":-13.857623,"twenty":-15.744841,"median":-14.662586,"eighty":-13.168057,"marketCap":14856734792.95}],"updateTime":1787815987823},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02493\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2649445601","title":"邁威生物－Ｂ(02493)股價下跌5.063%，現價港幣$24.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2649445601","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649445601?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 13:55","pubTimestamp":1783403700,"startTime":"0","endTime":"0","summary":"[下跌股]迈威生物－Ｂ(02493) 股价在下午01:54比前收市价下跌5.063%，现股价为港币$24.0。至目前为止，今日最高价为$25.58，而最低价为$24.0。总成交量为13.12万股，总成交金额为港币$324.689万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725133905145_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725133905145_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2607073380/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2607073380/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648368855","title":"邁威生物：截至2026年一季度末，公司在手現金及現金等價物餘額為14.83億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2648368855","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648368855?lang=zh_tw&edition=fundamental","pubTime":"2026-07-02 21:00","pubTimestamp":1782997200,"startTime":"0","endTime":"0","summary":"证券日报网7月2日讯，迈威生物在接受调研者提问时表示，截至2026年一季度末，公司在手现金及现金等价物余额为14.83亿元。此外，2026年4月28日，公司在香港联合交易所主板正式挂牌上市，募资净额约11.89亿港元。2026年及未来，创新研发仍然是公司长远发展的价值保障与核心战略，公司将根据核心管线的推进情况合理规划研发费用的投入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607023792165687.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607023792165687.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646648337","title":"邁威生物跌6.85% 2022年上市募34.77億國泰海通保薦","url":"https://stock-news.laohu8.com/highlight/detail?id=2646648337","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646648337?lang=zh_tw&edition=fundamental","pubTime":"2026-06-26 16:03","pubTimestamp":1782460982,"startTime":"0","endTime":"0","summary":"中国经济网北京6月26日讯 迈威生物 今日收报25.82元，跌幅6.85%。　　迈威生物首次公开发行股票的发行费用合计1.85亿元，其中，保荐承销费1.55亿元。　　迈威生物披露的上市公告书显示，海通证券安排子公司海通创新证券投资有限公司参与本次发行战略配售，配售数量为本次公开发行数量的2.88%，即287.3563万股，获配金额9999.9992万元；海通创新证券投资有限公司本次跟投获配股票的限售期为24个月，限售期自本次公开发行的股票在上交所上市之日起开始计算。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260626/32291042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0012","02611","BK1147","BK0028","BK0184","BK0201","BK1564","BK1161","BK0276","BK0183","IPOS","02493","BK0188","601211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646821717","title":"邁威生物－Ｂ(02493)股價顯著下跌11.253%，現價港幣$22.24","url":"https://stock-news.laohu8.com/highlight/detail?id=2646821717","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646821717?lang=zh_tw&edition=fundamental","pubTime":"2026-06-25 13:40","pubTimestamp":1782366000,"startTime":"0","endTime":"0","summary":"[下跌股]迈威生物－Ｂ(02493) 股价在下午01:40比前收市价显著下跌11.253%，现股价为港币$22.24。至目前为止，今日最高价为$25.04，而最低价为$22.24。总成交量为93.18万股，总成交金额为港币$2.169千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152743541_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152743541_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2606254098/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2606254098/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645131816","title":"邁威生物-B(02493.HK)：9MW5211注射液臨床試驗申請獲得國家藥品監督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2645131816","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645131816?lang=zh_tw&edition=fundamental","pubTime":"2026-06-24 21:53","pubTimestamp":1782309180,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645894983","title":"邁威生物：9MW5211注射液兩項適應症臨床試驗獲批 覆蓋多發性硬化、炎症性腸病","url":"https://stock-news.laohu8.com/highlight/detail?id=2645894983","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645894983?lang=zh_tw&edition=fundamental","pubTime":"2026-06-24 18:15","pubTimestamp":1782296100,"startTime":"0","endTime":"0","summary":"6月24日，迈威生物（688062/02493）发布公告，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，9MW5211注射液用于多发性硬化（MS）适应症的临床试验申请获得批准。此外，9MW5211用于炎症性肠病（IBD）适应症的临床试验申请也已获得批准，且公司正在积极推进其他多个适应症的临床试验申请工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606243781539226.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606243781539226.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645505866","title":"《股市簡訊》中國邁威生物A/H股齊漲，血液瘤藥物臨床試驗獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2645505866","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645505866?lang=zh_tw&edition=fundamental","pubTime":"2026-06-24 10:57","pubTimestamp":1782269829,"startTime":"0","endTime":"0","summary":"《股市简讯》中国迈威生物A/H股齐涨，血液瘤药物临床试验获批* 中国生物科技公司--迈威生物H股2493.HK周三早盘一度上扬2.4%，其A股688062.SS亦涨4.7%。* 该公司此前公告称，国家药品监督管理局批准注射用6MW5311用于血液瘤适应症的临床试验申请。* 迈威生物A股今年迄今跌27.5%，同期沪深300指数.CSI300上扬6%。* 中证医药100指数.CSI000978盘中一度升2.3%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nL4S42W08K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","688062","02493","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645880777","title":"邁威生物(688062.SH)：注射用6MW5311臨床試驗申請獲國家藥監局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2645880777","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645880777?lang=zh_tw&edition=fundamental","pubTime":"2026-06-23 18:37","pubTimestamp":1782211020,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物(688062.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，注射用6MW5311用于血液瘤(急性髓系白血病(AML)、慢性粒单核细胞白血病(CMML)以及多发性骨髓瘤(MM))适应症的临床试验申请获得批准。6MW5311是基于公司T Cell Engager(TCE)技术平台开发的一款靶向LILRB4/CD3的双特异性抗体，拟开发适应症为：血液瘤(AML、CMML以及MM)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688062","02493","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645557011","title":"智通港股早知道 | 八部門發布《關於加快「人工智能+消費」發展的實施意見》 伊朗軍方宣佈關閉霍爾木茲海峽","url":"https://stock-news.laohu8.com/highlight/detail?id=2645557011","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645557011?lang=zh_tw&edition=fundamental","pubTime":"2026-06-22 07:17","pubTimestamp":1782083861,"startTime":"0","endTime":"0","summary":"八部门发布《关于加快“人工智能+消费”发展的实施意见》18日，商务部等八部门发布《关于加快“人工智能+消费”发展的实施意见》，围绕提升人工智能+商品消费、扩大人工智能+服务消费等五方面，提出17项具体举措，促进人工智能进千家万户、进千商万店，更好满足人民美好生活需要。截至目前，工行、农行、中行、建行、交行均已宣布落地离岸人民币外汇试点交易。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456649.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0871576103.HKD","LU1048484197.HKD","LU0823397285.USD","IE00BPRC5H50.USD","01810","LU1674673691.USD","02302","LU0314109678.HKD","LU1981816686.USD","BK4604","LU1366334651.USD","LU2896262040.SGD","LU1481107354.HKD","LU2471134523.USD","LU1066051498.USD","LU0214875030.USD","LU0868486357.SGD","LU2471134879.HKD","LU1497734951.SGD","IE00BJLML261.HKD","LU0264606111.USD","IE0032431581.USD","SG9999006597.SGD","HK0000306685.HKD","LU0345769631.USD","01398","SG9999002562.SGD","LU2462157665.USD","LU2168564495.EUR","BK4592","LU1188198961.HKD","IE00BK4W5L77.USD","LU2148611432.USD","LU0345776255.USD","TSII","TLA","LU0516422440.USD","03328","LU0449515922.USD","SG9999003461.SGD","LU1719994722.HKD","LU1145028129.USD","LU1251922891.USD","LU1861220033.SGD","LU0039217434.USD","SG9999015986.USD","LU0163747925.USD","IE00BWDBJ730.SGD","LU0708995583.HKD","LU0886674414.USD","LU1861559042.SGD","LU0572944931.SGD","LU0323591593.USD","HK0001040143.USD","LU1720051108.HKD","LU0097036916.USD","LU1880383366.USD","LU2097828557.USD","BK4581","LU0084288322.USD","300750","LU1328277881.USD","LU1794554557.SGD","01164","LU1303224171.USD","BK1589","LU0823038988.USD","LU0531971595.HKD","LU1224709979.USD","TESL","LU0143863198.USD","LU0051755006.USD","LU0345769128.USD","LU0359201885.HKD","LU0823426480.USD","LU1008478684.HKD","TSYY","LU1914381329.SGD","BK1607","LU0823411888.USD","TSLZ","IE00BK4W5M84.HKD","TSDD","LU2108987350.USD","CICHY","LU0348814723.USD","BK4543","HK0000107257.USD","BK4551","LU1282648689.USD","LU2226246903.HKD","09766","LU2087589342.USD","TSL","LU1861215975.USD","TSLS","LU1504937902.USD","LU0054450605.USD","LU1807302812.USD","LU0169518387.USD","IE00B19Z8X17.USD","LU2756315664.SGD","LU2039709279.SGD","01288","LU0348735423.USD","LU2326559502.SGD","601988","BK1594","LU0700851271.USD","LU0791590937.USD","TSLW","BK1255","LU0823426308.USD","LU0228367735.SGD","LU0117841782.USD","TSLP","LU0077335932.USD","SG9999001051.SGD","LU0823414478.USD","LU0516422952.EUR","07366","LU1044875133.USD","IE00BVYPNQ40.USD","601328","LU0823413660.USD","TSLY","SG9999007991.SGD","SG9999015978.USD","LU0053666078.USD","LU0820562030.AUD","LU0234570918.USD","LU0943347566.SGD","SG9999013353.USD","TSLQ","LU0964807845.USD","LU0823039010.USD","81810","LU0456846285.SGD","LU0499858438.USD","LU0594300419.USD","BK4555","LU1568876335.HKD","TEST","BK1502","MIUmain","LU1044874839.SGD","LU0797268264.HKD","LU2360107168.USD","IE0034235303.USD","LU0831093199.SGD","LU0819123356.HKD","XIACY","LU0133085943.USD","LU0540923850.HKD","LU0082616367.USD","LU0173614495.USD","LU0359202008.SGD","LU0316494557.USD","BK1615","LU0210536198.USD","LU2476274720.SGD","LU0210526637.USD","LU1770034418.SGD","LU1548497426.USD","LU0630378429.USD","LU1629891620.HKD","IE00B19Z8W00.USD","LU0320764599.SGD","BK4511","BK1227","IE00BWXC8680.SGD","BK1575","BK4585","LU1323998911.USD","LU1051769294.HKD","SG9999001069.SGD","HK0000286598.CNH","SG9999002463.SGD","LU1023057109.AUD","BK1124","LU2417539215.USD","LU1242518931.SGD","LU1634259391.SGD","IE00B1BXHZ80.USD","LU0449509016.USD","BK4598","LU0820561909.HKD","LU0708995401.HKD","LU2168564149.EUR","LU1282651121.HKD","LU2168563687.JPY","LU0588545904.SGD","LU0634319403.HKD","IE00BGHQDM52.EUR","BK1521","LU0561508036.HKD","LU0588545730.USD","03988","LU0719512351.SGD","HK0001040168.HKD","LU0918141887.USD","LU2476274308.USD","LU0918141705.HKD","LU0823040885.USD","LU1435385759.SGD","LU0880133367.SGD","IE00BVYPNP33.GBP","LU1778281490.HKD","TSLL","LU0072462343.USD","LU2097828805.USD","LU1642822792.SGD","01392","LU0469268626.HKD","LU0572940350.SGD","LU1831875114.USD","LU2249611893.SGD","LU0052750758.USD","LU0315179316.USD","LU2063271972.USD","SG9999015952.SGD","HK0000288743.USD","LU1232071149.USD","LU0164880469.USD","LU0320765059.SGD","LU0672654240.SGD","LU2750360997.AUD","LU0441854154.USD","LU2213484517.USD","01140","BK1523","LU1048596156.SGD","LU2778985437.USD","LU0259732245.USD","LU0348825331.USD","LU1152091168.USD","SG9999001093.SGD","BK1178","HK0000165453.HKD","TSLR","LU1152091754.HKD","LU1224444064.USD","BK4548","LU1497733631.SGD","LU0234572021.USD","BK1156","LU0823413587.USD","LU2420271590.USD","BK1610","BK4527","LU1242518857.USD","LU1522347837.USD","LU2087621335.USD","03750","IE00B1XK9C88.USD","LU0456827905.SGD","BK4574","LU1852331112.SGD","LU0143863784.USD","LU0650527681.SGD","LU1267930730.SGD","LU2357305700.SGD","LU0235996351.USD","LU2097828631.EUR","TSLA","601398","LU0056508442.USD","LU1993786604.SGD","LU1960683339.HKD","LU1568876251.USD","LU2403377893.USD","LU0165289439.USD","LU0683595622.HKD","07766","00939","LU0605514214.HKD","BK4533","LU0198837287.USD","IE00BQJZWZ67.USD","LU1839511570.USD","LU0463099449.HKD","LU1674673428.USD","SG9999001226.SGD","BK1117","LU0675040207.SGD","LU1366334578.USD","LU0396098781.USD","TSLO","LU0820561818.USD","LU0348816934.USD","HK0000306701.USD","LU0819121731.USD","LU0856984785.SGD","LU0315178854.USD","LU1808992512.USD","LU1720050803.USD","LU0588545490.SGD","LU1961090484.USD","LU2023250330.USD","BK1231","LU0164872284.USD","LU0348805143.USD","LU0593848301.USD","LU1880383440.USD","HK0000320264.USD","ACGBY","LU0499858602.USD","LU2750360641.GBP","SGXZ90724238.SGD","LU0516422366.SGD","688062","BK1506","LU2360106780.USD","LU2152927971.USD","LU2097828714.EUR","BK1116","LU2168564222.USD","LU0149534421.HKD","SG9999014674.SGD","LU1515016050.SGD","LU0307460666.USD","IE00B5MMRT66.SGD","SG9999009443.AUD","LU0348723411.USD","LU0516423174.USD","LU0762540952.USD","LU0164865239.USD","LU1066051811.HKD","LU1366192091.USD","LU2602419157.SGD","LU0359201612.USD","LU1048588211.SGD","09366","03143","LU0821914370.USD","BK1161","HK0000914660.USD","LU0327786744.USD","LU0607220059.USD","LU0823397103.USD","LU2097828474.EUR","LU2756315318.SGD","LU1066051225.USD","LU2250418816.HKD","601288","LU1551013425.SGD","LU0865486749.SGD","HXXD.SI","LU0531970944.HKD","LU2456880835.USD","LU0466842654.USD","LU1868837565.USD","BK4516","LU0254981946.USD","LU1551013342.USD","LU2294711473.HKD","LU1044876610.USD","LU2236285917.USD","IE00B543WZ88.USD","LU0293314216.USD","LU0109391861.USD","TSLI","BACHY","HK0000914686.HKD","IE00B3M56506.USD","LU0611395673.USD","LU2257852520.SGD","LU2399975544.HKD","LU2471134796.USD","LU0979878070.USD","BK1220","LU0633140727.USD","LU1813983027.USD","LU1861558580.USD","BK1560","LU1105468828.SGD","IDCBY","BK1524","LU0047713382.USD","LU0370786039.SGD","LU0345775950.USD","TSLG","LU2290526834.HKD","LU0287142896.SGD","00306","SG9999004220.SGD","IE00B19Z9505.USD","LU0594300179.USD","LU2449936058.SGD","LU0823041008.USD","LU0244354667.USD","LU0431992006.USD","LU1497733557.USD","LU0572939691.SGD","LU1868838027.USD","BK1193","BK4612","LU0633140560.USD","IE00BMCWC346.EUR","LU1211504680.USD","00417","BK4099","BCMXY","LU1720051017.SGD","02513","HK0000320223.HKD","LU0516423091.SGD","LU0791591158.USD","LU1770036033.HKD","LU0048580855.USD","LU2471134952.CNY","LU0348827113.USD","LU0651946864.USD","LU0689472784.USD","LU0061477393.USD","CRSH","LU0149721374.USD","BK1618","LU1051768304.USD","LU0588546209.SGD","LU1429558221.USD","LU0417516738.SGD","BK4534","LU0651947912.USD","LU0345770308.USD","SG9999002828.SGD","LU1956131251.USD","IE0003895053.USD","LU0211977185.USD","LU0345770993.USD","BK1545","IE00BYV24P56.USD","LU0417516902.SGD","TSLT","601939","LU0140636845.USD","IE00B0JY6N72.USD","LU1634259557.SGD","BK4588","LU0043850808.USD","LU0326950275.SGD","LU2213496289.HKD","LU1282651048.USD","02493","IE00B19Z5X02.USD","HK0000288784.HKD","BK1592","BK4550","LU1066053197.SGD","IE0034224299.USD","LU2168564065.EUR","LU0067412154.USD","LU0231483743.USD","LU0737861699.HKD","IE00BSNM7G36.USD","LU0096374516.USD","SG9999015945.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644008119","title":"邁威生物-B(02493)：9MW2821在2026年歐洲腫瘤內科學會婦科腫瘤年會 (ESMO Gynae)以口頭報告和壁報形式報告最新臨床數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2644008119","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644008119?lang=zh_tw&edition=fundamental","pubTime":"2026-06-18 22:17","pubTimestamp":1781792248,"startTime":"0","endTime":"0","summary":"9MW2821给药后，可与肿瘤细胞表面的Nectin-4结合并进入细胞，通过酶解作用，定向释放细胞毒素，从而实现对肿瘤的精准杀伤。截至2025年3月20日，53例可评估疗效的患者经确认的ORR和 DCR 分别为32.08%和81.13%。中位mOS为19.4个月，12个月OS率为 72.7%，24个月OS率为49.1%。mPFS和mDOR 分别为4.0个月和9.1个月，mOS尚未达到，12个月OS率为76.6%，24个月OS率为 51.1%。截至2026年3月19日，该研究队列共入组19例患者接受BFv联合特瑞普利单抗治疗，其中3例为既往经治，16例为初治患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644815380","title":"邁威生物-B(02493)：華俊獲委任為授權代表","url":"https://stock-news.laohu8.com/highlight/detail?id=2644815380","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644815380?lang=zh_tw&edition=fundamental","pubTime":"2026-06-18 22:02","pubTimestamp":1781791376,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物-B(02493)发布公告，自2026年6月18日起：胡会国先生不再担任公司于香港联合交易所有限公司证券上市规则第3.05条项下授权代表的职务;及公司的执行董事华俊先生获委任为授权代表。于华俊先生获委任后，公司的授权代表为华俊先生及梁君慧女士。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644276089","title":"邁威生物-B(02493)：桂勳獲選舉為職工代表董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2644276089","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644276089?lang=zh_tw&edition=fundamental","pubTime":"2026-06-18 21:50","pubTimestamp":1781790608,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物-B(02493)发布公告，于2026年6月18日召开的工会委员会上，桂勋博士在公司于2026年6月18日举行的第一届工会委员会第七次会议暨公司职工代表大会上获选举为公司第三届董事会职工代表董事。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456460.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644208599","title":"邁威生物完成董事會換屆：劉大濤當選董事長並任總經理","url":"https://stock-news.laohu8.com/highlight/detail?id=2644208599","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644208599?lang=zh_tw&edition=fundamental","pubTime":"2026-06-18 20:27","pubTimestamp":1781785620,"startTime":"0","endTime":"0","summary":"6月18日，迈威生物（688062/02493）发布公告，公司召开会议完成第三届董事会的换届选举，其中刘大涛被选为董事长，桂勋被选为职工代表董事。此外，公司聘任了多名高级管理人员，刘大涛担任总经理，HAIWU（武海）、桂勋、王树海、胡会国、李瀚等担任副总经理，华俊任副总经理、财务负责人，王鹤飞任董事会秘书，高戈任证券事务代表。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606183776363418.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606183776363418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644763257","title":"邁威生物－Ｂ(02493)股價上升5.098%，現價港幣$26.8","url":"https://stock-news.laohu8.com/highlight/detail?id=2644763257","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644763257?lang=zh_tw&edition=fundamental","pubTime":"2026-06-18 10:15","pubTimestamp":1781748900,"startTime":"0","endTime":"0","summary":"[上升股]迈威生物－Ｂ(02493) 股价在上午10:14比前收市价上升5.098%，现股价为港币$26.8。至目前为止，今日最高价为$26.8，而最低价为$25.44。总成交量为13.16万股，总成交金额为港币$344.139万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2606181209/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2606181209/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644797482","title":"港股異動 | 邁威生物-B(02493)升逾3% 旗下邁威視與維眸生物達成戰略合作 聚焦眼科炎症及眼免疫領域","url":"https://stock-news.laohu8.com/highlight/detail?id=2644797482","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644797482?lang=zh_tw&edition=fundamental","pubTime":"2026-06-17 11:38","pubTimestamp":1781667515,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，迈威生物-B涨超3%，截至发稿，涨2.72%，报26.48港元，成交额648.46万港元。消息面上，6月16日，据迈威生物官微消息，公司宣布其控股子公司迈威视与国内领先的眼科小分子药物研发企业维眸生物达成战略合作。据介绍，迈威生物视拥多款眼底产品，包括9MW0211抗VEGF单抗创新药、阿达木单抗生物类似药、阿柏西普生物类似药，并覆盖眼免疫药物、眼底病药物、以及干眼和眼表等领域的成熟药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455390.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","02493","BK4585","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643248082","title":"《股市簡訊》中國邁威生物勁揚6.4%，美國FDA批准其血液瘤藥物臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2643248082","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643248082?lang=zh_tw&edition=fundamental","pubTime":"2026-06-15 12:02","pubTimestamp":1781496152,"startTime":"0","endTime":"0","summary":"《股市简讯》中国迈威生物劲扬6.4%，美国FDA批准其血液瘤药物临床试验* 中国生物科技公司--迈威生物2493.HK周一早盘劲升6.4%。* 该公司此前公告称，美国食品药品监督管理局（FDA）许可了注射用6MW5311用于血液瘤（急性髓系白血病、慢性粒单核细胞白血病以及多发性骨髓瘤）适应症的临床试验申请。* 恒⽣⽣物科技指数.HSBIO盘中一度涨1.4%。（完）更多股市简讯请点选CN-CMN-HOT (发稿 徐凯文；审校 田镧沁) ((kaiwen.xu@thomsonreuters.com))","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nL4T42N08V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643217232","title":"港股異動 | 邁威生物-B(02493)午前升逾6% 注射用6MW5311臨床試驗申請獲得FDA許可","url":"https://stock-news.laohu8.com/highlight/detail?id=2643217232","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643217232?lang=zh_tw&edition=fundamental","pubTime":"2026-06-15 11:51","pubTimestamp":1781495491,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，迈威生物-B午前涨超6%，截至发稿，涨6.22%，报26.66港元，成交额1256.09万港元。消息面上，迈威生物-B发布公告，近日，迈威(上海)生物科技股份有限公司收到美国食品药品监督管理局签发的《临床研究继续进行通知书》，注射用6MW5311用于血液瘤适应症的临床试验申请正式获得FDA许可。此外，6MW5311临床试验申请已获得国家药品监督管理局受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","LABU","BK1161","02493","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643226122","title":"邁威生物(02493.HK)注射用6MW5311臨床試驗申請獲FDA許可","url":"https://stock-news.laohu8.com/highlight/detail?id=2643226122","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643226122?lang=zh_tw&edition=fundamental","pubTime":"2026-06-15 09:30","pubTimestamp":1781487000,"startTime":"0","endTime":"0","summary":"迈威生物－Ｂ(02493.HK) 公布，收到美国食品药品监督管理局(FDA)签发的《临床研究继续进行通知书》，注射用6MW5311用于血液瘤(急性髓系白血病)(AML)、慢性粒单核细胞白血病(CMML)以及多发性骨髓瘤(MM)适应症的临床试验申请正式获得FDA许可。此外，6MW5311临床试验申请已获得国家药品监督管理局受理。(sl/u)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20260420093816116_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20260420093816116_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1528979/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1528979/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642026565","title":"邁威生物(688062.SH)：注射用6MW5311臨床試驗申請獲得FDA許可","url":"https://stock-news.laohu8.com/highlight/detail?id=2642026565","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642026565?lang=zh_tw&edition=fundamental","pubTime":"2026-06-12 16:25","pubTimestamp":1781252747,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物(688062.SH)发布公告，近日，公司收到美国食品药品监督管理局(FDA)签发的《临床研究继续进行通知书》，注射用6MW5311用于血液瘤(急性髓系白血病(AML)、慢性粒单核细胞白血病(CMML)以及多发性骨髓瘤(MM))适应症的临床试验申请正式获得FDA许可。此外，6MW5311临床试验申请已获得国家药品监督管理局受理。6MW5311为全球首款获批开展临床试验的靶向LILRB4/CD3的TCE创新药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1161","BK0239","LABU","688062","BK4585","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642826340","title":"重磅單品凸顯聯用潛力，邁威生物-B(02493)商業化確定性逐步兑現","url":"https://stock-news.laohu8.com/highlight/detail?id=2642826340","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642826340?lang=zh_tw&edition=fundamental","pubTime":"2026-06-12 16:12","pubTimestamp":1781251936,"startTime":"0","endTime":"0","summary":"2026年过半，迈威生物-B正站在新一轮价值重估的起跑线上。截至目前，9MW2821已开展4项III期关键注册临床，3项适应症获FDA快速通道认定，1项适应症获孤儿药认定，2项适应症获CDE纳入突破性治疗品种名单。本次9MW2821与特瑞普利单抗的组合同样在临床试验中展现出优秀疗效，无疑再度验证了这一联用疗法的潜力。该药计划于2026年下半年开展治疗COPD的III期临床试验，若成功，有望成为国产首款获批的靶向ST2单抗，商业化前景不容小觑。近日，该药品注射","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":86,"code":"91000000","status":"200"}]}}